Optimizing Chronic Cough Phase 3 Trials With Point-Of-Need Eye Assessments

Collaboration was key in overcoming challenges during Company W's chronic cough study, which required an ocular substudy to meet FDA mandates. Non-ophthalmic trial sites specializing in respiratory treatments faced significant hurdles, including limited resources for ocular assessments and logistical difficulties.
20/20 Onsite offered a tailored solution, providing mobile vision services and custom onboarding for site personnel. This collaboration fostered seamless integration of the ocular substudy, reducing administrative burdens and ensuring compliance with study protocols. By addressing site-specific needs and streamlining processes, 20/20 Onsite demonstrates the value of strategic collaboration in optimizing non-ophthalmic clinical trials.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.